Evolus Inc.

EOLS | NASDAQ

Price Alert Chart Builder DCF Calculator

$7.99

+$0.13 (+1.65%)

At close: Sep 21, 2026, 4:00 PM ET

+$0.01 (+0.13%)

Pre-market: Sep 22, 2026, 7:00 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

Company Profile

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.

Key Executives

Name	Position
David Moatazedi	President, Chief Executive Officer & Director
Tatjana Mitchell	Chief Financial Officer
Jeffrey J. Plumer	Corporate Secretary
Jessica Novak	Senior Vice President of Human Resources
Kurt Knab	Senior Vice President of Sales
Nareg Sagherian	Head of Global Investor Relations & Corporate Communications
Rui Avelar C.CFP Dip.SportMed	Chief Medical Officer and Head of Research & Development

Latest SEC Filings

Date	Type	Title
Sep 04, 2026	4	Filing
Aug 31, 2026	SC 13G	Statement of acquisition of beneficial ownership b...
Aug 05, 2026	10-Q	Quarterly Report
Aug 05, 2026	8-K	Current Report
Aug 04, 2026	8-K	Current Report
Jul 08, 2026	8-K	Current Report
Jun 12, 2026	EFFECT	Filing
Jun 12, 2026	8-K	Current Report
Jun 05, 2026	S-3	Filing
May 04, 2026	10-Q	Quarterly Report

View All SEC Filings ➞

Evolus Inc.

Country	United States
IPO Date	Feb 7, 2018
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	353
CEO	David Moatazedi

Contact Details

520 Newport Center Drive Newport Beach, California 92660 United States

https://www.evolus.com

949 284 4555

Stock Details

Ticker Symbol	EOLS
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001570562
CUSIP Number	30052C107
ISIN Number	US30052C1071
SIC Code	2834